Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LXRX Lexicon Pharmaceuticals

Market Closed 09-25 16:00:00 EDT

1.80

-0.06

-3.49%

盘后1.82

+0.03+1.39%

19:59 EDT

High1.93	Low1.77	Vol3.05M
Open1.87	D1 Closing1.86	Amplitude8.87%
Mkt Cap796.98M	Tradable Cap395.65M	Total Shares444.00M
T/O5.61M	T/O Rate1.38%	Tradable Shares220.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LXRX","market":"US","secType":"STK","nameCN":"Lexicon Pharmaceuticals","latestPrice":1.795,"timestamp":1790366400000,"preClose":1.86,"halted":0,"volume":3050402,"hourTrading":{"tag":"盘后","latestPrice":1.82,"preClose":1.795,"latestTime":"19:59 EDT","volume":42833,"amount":77359.8964,"timestamp":1790380792992,"change":0.025,"changeRate":0.013928,"amplitude":0.04117},"delay":0,"changeRate":-0.03494623655913987,"floatShares":220415134,"shares":444000000,"eps":-0.158737,"marketStatus":"Market Closed","change":-0.065,"latestTime":"09-25 16:00:00 EDT","open":1.87,"high":1.93,"low":1.765,"amount":5610749.5977352,"amplitude":0.08871,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.158737,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790582400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":955080000000,"exchange":"NASDAQ","adjPreClose":1.86,"preHourTrading":{"tag":"盘前","latestPrice":1.9,"preClose":1.86,"latestTime":"09:08 EDT","volume":4744,"amount":9053.509374399999,"timestamp":1790341724824,"change":0.04,"changeRate":0.021505,"amplitude":0.027258},"postHourTrading":{"tag":"盘后","latestPrice":1.82,"preClose":1.795,"latestTime":"19:59 EDT","volume":42833,"amount":77359.8964,"timestamp":1790380792992,"change":0.025,"changeRate":0.013928,"amplitude":0.04117},"volumeRatio":0.6801949795808936,"impliedVol":0.4818,"impliedVolPercentile":0.0916},"requestUrl":"/m/hq/s/LXRX","defaultTab":"news","newsList":[{"id":"2666547902","title":"Lexicon Pharmaceuticals (LXRX) Receives a Buy from Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2666547902","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666547902?lang=en_us&edition=fundamental","pubTime":"2026-09-11 16:25","pubTimestamp":1789115123,"startTime":"0","endTime":"0","summary":"Citi analyst Yigal Nochomovitz maintained a Buy rating on Lexicon Pharmaceuticals yesterday and set a price target of $3.10. The company’s shares c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lexicon-pharmaceuticals-lxrx-receives-a-buy-from-citi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lexicon-pharmaceuticals-lxrx-receives-a-buy-from-citi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664866227","title":"Lexicon to Present at Citi Biopharma Back to School Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664866227","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664866227?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:09","pubTimestamp":1788293352,"startTime":"0","endTime":"0","summary":"Lexicon to present at Citi Biopharma Back to School investor conferenceLexicon Pharmaceuticals management is scheduled to present at three investor conferences in New York on Sept. 9-10, 2026, and Sep","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL1jg6kc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BN0W2V16.EUR","FTXO","LU1267930227.SGD","LU0162691827.USD","LU0203347892.USD","LU1144417596.USD","LU2456880835.USD","TFNS","BCDF","SG9999014013.SGD","LU2210149790.SGD","LU1506573853.SGD","BK4504","LU0170899867.USD","LU0477156953.USD","LU2360032135.SGD","LU2462157665.USD","LU1668664300.SGD","LU1366192091.USD","LU2236285917.USD","BK4585","LU1791807156.HKD","LU0130517989.USD","IYF","IE00BN0W2W23.USD","LU2417539215.USD","IE00BSNM7G36.USD","LXRX","LU1244550494.USD","LU0320765646.SGD","SG9999014021.USD","LU2125154935.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0648001328.SGD","BK4559","LU0098860793.USD","LU0203345920.USD","LU0128525689.USD","IE00BQXX3C00.GBP","LU0314104364.USD","LU1201861249.SGD","BK4207","LU1244550221.USD","IE00BQXX3F31.USD","LU0980610538.SGD","IE00B3QW5Z07.USD","LU0314106906.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664682388","title":"Why Lexicon Pharmaceuticals (LXRX) Is Back In The Spotlight","url":"https://stock-news.laohu8.com/highlight/detail?id=2664682388","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664682388?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:26","pubTimestamp":1788272804,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (LXRX) has drawn fresh attention after new SOLOIST-WHF Phase 3 post hoc data on sotagliflozin were shared at ESC Congress 2026. The findings reinforce consistent efficacy and safety across baseline blood pressure in high risk heart failure patients.\nDespite the new SOLOIST-WHF data, Lexicon Pharmaceuticals’ share price has softened in the very short term, with a 1-day share price return of 1.75% and a 7-day share price return of 3.85%. However, a 90-day share price...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxrx/lexicon-pharmaceuticals/news/why-lexicon-pharmaceuticals-lxrx-is-back-in-the-spotlight","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxrx/lexicon-pharmaceuticals/news/why-lexicon-pharmaceuticals-lxrx-is-back-in-the-spotlight","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4007","LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663055420","title":"Lexicon announces results from post hoc analysis of SOLOIST-WHF trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2663055420","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663055420?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:55","pubTimestamp":1788180939,"startTime":"0","endTime":"0","summary":"Lexicon (LXRX) announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial evaluating the efficacy and safety of sotagliflozin acro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-announces-results-from-post-hoc-analysis-of-soloist-whf-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-announces-results-from-post-hoc-analysis-of-soloist-whf-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4135","BK4139","LXRX","BK4007","WHF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663003697","title":"Lexicon Post Hoc Soloist-WHF Analysis Shows Sotagliflozin Benefit Holds Across Baseline Blood Pressure Levels","url":"https://stock-news.laohu8.com/highlight/detail?id=2663003697","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663003697?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:32","pubTimestamp":1788179553,"startTime":"0","endTime":"0","summary":"Lexicon post hoc SOLOIST-WHF analysis shows sotagliflozin benefit holds across baseline blood pressure levelsLexicon Pharmaceuticals reported a post hoc analysis from the Phase 3 SOLOIST-WHF trial of ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL4GzkKm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BGHQF748.EUR","SG9999014005.SGD","LXRX","NDAQ","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BCDF","LU2210150020.SGD","BK4007","BK4585","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","SG9999014039.USD","BK4588","IE00BN0W2W23.USD","SG9999014021.USD","LU2210149790.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661277313","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661277313","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661277313?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:50","pubTimestamp":1787583009,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT). Lexicon Pharma...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-lexicon-pharmaceuticals-lxrx-and-maxcyte-mxct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-lexicon-pharmaceuticals-lxrx-and-maxcyte-mxct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4539","BK4588","BK4137","BK4581","LABU","LU0128526141.USD","BK4139","HCSG","LXRX","LU0029874061.USD","MXCT","BK4121","BK4585","XBI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271595","title":"Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271595","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271595?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:12","pubTimestamp":1787577120,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals has earned a third $10 million milestone payment from Novo Nordisk for hitting a key milestone in the clinical development program for its obesity drug.The biopharmaceutical company on Monday said that it has achieved a patient dosing milestone in the continuing phase 1 program for LX9851, a treatment being developed for obesity and associated metabolic disorders.Lexicon and Novo Nordisk signed an exclusive worldwide license agreement for LX9851 last year, under which Novo Nordisk is able to develop, manufacture and commercialize the drug for all indications.So far, Lexicon has earned $75 million of the $1 billion in potential upfront, development, regulatory and commercial milestone payments available under its Novo Nordisk collaboration. Lexicon is also entitled to receive tiered royalties on future LX9851 sales.The development program for LX9851 was kicked off by Novo Nordisk in March to investigate the safety, tolerability, pharmacokinetics and pharmacodynam","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOH","LU1093756325.SGD","BK4007","LU1093756168.USD","OZEM","BK4588","IE00BKVL7J92.USD","BK4585","NVOC","BK4139","LXRX","NVO","THNR","BK4532","NVOX","IE00BZ1G4Q59.USD","LU0154236417.USD","PPH","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661279033","title":"Lexicon earns third $10M milestone payment from Novo Nordisk for LX9851","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279033","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661279033?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:45","pubTimestamp":1787575521,"startTime":"0","endTime":"0","summary":"Lexicon (LXRX) announced that it has earned a third $10M milestone payment in 2026 from Novo Nordisk (NVO) following the achievement of a patient d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-earns-third-10m-milestone-payment-from-novo-nordisk-for-lx9851-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-earns-third-10m-milestone-payment-from-novo-nordisk-for-lx9851-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX","LU1093756325.SGD","BK4585","BK4007","OZEM","NVOX","BK4532","LU0154236417.USD","NVOC","BK4139","PPH","IE00BKVL7J92.USD","BK4588","NVO","LU1093756168.USD","THNR","NVOH","BK4599","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661792276","title":"Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for Lx9851","url":"https://stock-news.laohu8.com/highlight/detail?id=2661792276","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661792276?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:30","pubTimestamp":1787574601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA9TSMSL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LXRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661276796","title":"Lexicon Pharmaceuticals, - Has Earned $75 Mln of $1 Bln Potential Milestone Payments from Novo Nordisk","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276796?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:30","pubTimestamp":1787574601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA9TSMSL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXRX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661276717","title":"Lexicon Pharmaceuticals, - Eligible for up to $1 Bln in Upfront and Milestone Payments Plus Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276717","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276717?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:30","pubTimestamp":1787574601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA9TSMSL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936984","title":"Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936984","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936984?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:00","pubTimestamp":1786359600,"startTime":"0","endTime":"0","summary":"Major Regulatory Milestone Positions Company to Initiate Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination Lucid-MS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341697/0/en/quantum-biopharma-receives-united-states-fda-clearance-to-proceed-with-lucid-ms-phase-2-trial-in-progressive-multiple-sclerosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","LU0889565916.HKD","IAK","BK4532","PBE","IE0005OL40V9.USD","LU0320765992.SGD","BMED","KBWP","IE00B775H168.HKD","BK4099","NVIB","BK4007","IE00BN29S564.USD","LABU","BIIB","LCDL","LU2089284900.SGD","UBCP","IE00BZ1G4Q59.USD","QNTM","LU1481011671.HKD","LU0912757837.SGD","LU0731783394.SGD","BK4596","LCID","LU1668664300.SGD","PGR","LU0070302665.USD","BNDI","LU1035773651.USD","NBIX","LU1718418525.SGD","IE0004445015.USD","LU1366192091.USD","LU1988902786.USD","KBWB","IND","LU0053666078.USD","LU2087625088.SGD","BK4139","BK4504","CAGR","BK4516","LU0971096721.USD","LCIZ","IAI","LU0772969993.USD","LU2065170008.USD","LU1244550221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657464752","title":"Lexicon Pharmaceuticals (LXRX) Receives a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2657464752","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657464752?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:28","pubTimestamp":1786116489,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Lexicon Pharmaceuticals today and set a price target of $6.00. Rahimi covers the He...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lexicon-pharmaceuticals-lxrx-receives-a-buy-from-piper-sandler-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lexicon-pharmaceuticals-lxrx-receives-a-buy-from-piper-sandler-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657655696","title":"Lexicon Pharmaceuticals - to Offer up to 1,257,856 Shares of Common Stock Issuable to Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2657655696","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657655696?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:09","pubTimestamp":1786050542,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN443245:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657632415","title":"Lexicon Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657632415","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657632415?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:32","pubTimestamp":1786023170,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings SummaryLexicon Pharmaceuticals IncLXRX.OQreported a quarterly adjusted loss of 7 cents per share for the quarter en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LXRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636841","title":"Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, vs. FactSet Est of $0.05 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636841","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636841?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:56","pubTimestamp":1786017417,"startTime":"0","endTime":"0","summary":"Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, vs. FactSet Est of $0.05 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657635088","title":"Lexicon Pharmaceuticals Posts Q2 Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657635088","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657635088?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:52","pubTimestamp":1786017121,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals posts Q2 net lossOverviewUS biopharmaceutical firm's Q2 revenue fell sharply yr/yrCompany posted Q2 net loss after higher research costs for SONATA-HCM trialCash and investment","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430LM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0320765992.SGD","STOK","LXRX","BK4007","RCUS","BK4588","BK4139","BK4585","EYPT","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657635732","title":"Lexicon Pharmaceuticals Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $692.000K Miss $3.998M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657635732","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657635732?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:48","pubTimestamp":1786016913,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 800 percent decrease over earnings of $0.01 per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60990373/lexicon-pharmaceuticals-q2-eps-0-07-misses-0-05-estimate-sales-692-000k-miss-3-998m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657353026","title":"Lexicon Q2 FY26 Net Loss Widens to $31.8 Million; Revenue Drops to $0.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657353026","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657353026?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:36","pubTimestamp":1786016178,"startTime":"0","endTime":"0","summary":"Lexicon Q2 FY26 net loss widens to $31.8 million; revenue drops to $0.7 millionLexicon posted Q2 2026 revenue of $0.7 million, down 97.58% from a year earlier.Net loss widened to $31.8 million, or $0.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL1bLbVj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HTGC","PBDC","PEX","BIZD","BK4135","BK4007","LXRX","BK4139","FBDC","FXED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633237","title":"Lexicon Pharmaceuticals Q2 Basic EPS USD -0.07","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633237?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:30","pubTimestamp":1786015805,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXVJWQH0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXRX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lexpharma.com","stockEarnings":[{"period":"1week","weight":-0.1244},{"period":"1month","weight":-0.2229},{"period":"3month","weight":-0.2961},{"period":"6month","weight":0.0879},{"period":"1year","weight":0.3396},{"period":"ytd","weight":0.5609}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0069},{"period":"3month","weight":0.0581},{"period":"6month","weight":0.2165},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.040884},{"month":2,"riseRate":0.423077,"avgChangeRate":-0.046623},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016324},{"month":4,"riseRate":0.461538,"avgChangeRate":0.013505},{"month":5,"riseRate":0.518519,"avgChangeRate":0.041126},{"month":6,"riseRate":0.666667,"avgChangeRate":0.133521},{"month":7,"riseRate":0.481481,"avgChangeRate":0.019303},{"month":8,"riseRate":0.259259,"avgChangeRate":-0.025305},{"month":9,"riseRate":0.333333,"avgChangeRate":0.003227},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.006481},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.041818},{"month":12,"riseRate":0.461538,"avgChangeRate":0.062158}],"exchange":"NASDAQ","name":"Lexicon Pharmaceuticals","nameEN":"Lexicon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lexicon Pharmaceuticals,LXRX,Lexicon Pharmaceuticals股票,Lexicon Pharmaceuticals股票老虎,Lexicon Pharmaceuticals股票老虎国际,Lexicon Pharmaceuticals行情,Lexicon Pharmaceuticals股票行情,Lexicon Pharmaceuticals股价,Lexicon Pharmaceuticals股市,Lexicon Pharmaceuticals股票价格,Lexicon Pharmaceuticals股票交易,Lexicon Pharmaceuticals股票购买,Lexicon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}